Lipid-lowering drugs and inflammatory bowel disease's risk: a drug-target Mendelian randomization study.

ABSTRACT:

Background

Inflammatory bowel disease (IBD) has been associated with lipid-lowering drugs in observational studies. Drug-target Mendelian randomization (MR) was utilized in this study to examine the causal relationship between lipid-lowering drugs and incidence of IBD, aiming to identify new preventive uses for the drugs.

Methods

We identified instrumental variables for three classes of lipid-lowering drugs: HMGCR inhibitors, PCSK9 inhibitors, and NPC1L1 inhibitors, using data from the Global Lipids Genetics Consortium. Summary statistics of IBD were obtained from UK Inflammatory Bowel Disease Genetics. The summary-data-based MR (SMR) and the inverse-variance weighted (IVW) MR were used for analysis. Sensitivity analyses were performed by conventional MR methods.

Results<

SUBMITTER: Zhao J 

PROVIDER: S-EPMC10775535 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature